Nutriband
$4.92 -0.0200 +5.08% 1.9K
Standing at the forefront of addressing the global opioid crisis
Company Overview
Nutriband is a pioneering US-based pharmaceutical company focused on the development and commercialization of transdermal technologies that improve the safety, comfort, and efficacy of FDA-approved drugs, benefitting patients, physicians, and payers. Nutriband’s lead product technology, AVERSA™, is an abuse deterrent transdermal technology that incorporates aversive agents to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential, such as opioids, a $22.8 billion global market.
The Company’s first application for AVERSA™ is an abuse-deterrent fentanyl transdermal patch which it is being developed to provide clinicians and patients a safe extended-release patch for chronic pain. The goal is to make opioid-based pain treatments safe for all who need them. AVERSA™ technology has received patent protection in the US, EU, Australia, Japan, Mexico, and Russia, with patent protection pending in Canada. With anticipated peak annual sales of up to $200 million upon FDA approval, and a strategic partnership with Kindeva for commercial development, Nutriband stands poised for significant growth. Nutriband's diversified structure, including revenue-generating subsidiaries and in-house manufacturing capabilities, solidifies its position as a unique player in the biopharma sector, promising investors a blend of innovation, sustainability, and market potential.
Value Proposition
Nutriband presents a compelling opportunity, standing at the forefront of addressing the global opioid crisis with its revolutionary AVERSA™ abuse-deterrent transdermal technology. Nutriband’s lead product, AVERSA™ Fentanyl, is targeting peak annual sales of $80 million to $200 million upon FDA approval. Nutriband is pursuing a streamlined 505(b)(2) NDA regulatory pathway for AVERSA™ Fentanyl, requiring only a single Phase 1 trial with the potential for an expedited six-month FDA review further accelerates the path to market.
Nutriband's robust IP portfolio, with patents secured in major markets worldwide and additional patents pending, safeguards its innovations, ensuring long-term competitiveness and market exclusivity. The company's diversified business model, bolstered by revenue-generating subsidiaries, provides a strong foundation and minimizes reliance on external funding for R&D.
Nutriband embodies a unique convergence of innovation, significant societal value, and strong growth prospects. With a streamlined path to market, clear vision, established strategic partnerships, and commitment to addressing one of healthcare's most pressing challenges, Nutriband is well-positioned for success.
Investor Presentation
Investment Highlights
- Revolutionary AVERSA™ abuse-deterrent transdermal technology mitigates the risk of drug abuse, diversion, and accidental exposure
- Targeting opioid crisis with AVERSA™ Fentanyl – addressing a global market valued at $22.8 billion
- AVERSA™ Fentanyl anticipated to reach peak annual sales of $80 million to $200 million upon FDA approval
- Streamlined 505(b)(2) NDA regulatory pathway requires only a single Phase 1 trial, significantly reducing the time and cost of development
- AVERSA™ Fentanyl is eligible for an expedited six-month FDA review
- Strong IP with patent protection in major markets including the US, EU, Australia, Japan, Mexico, and Russia, with pending patents in Canada
- Diversified business model includes revenue-generating subsidiaries that support the company's financial sustainability and reduce its reliance on external funding for research and development activities
Sign Up For NTRB Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
Nutriband (NTRB) is a client of RedChip Companies, Inc. NTRB agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in April 2024, and 50,000 options with a $3 strike price and 50,000 options with a $6.43 strike price, all options having a three year term, for 12 month of investor awareness services. In an amended contract, signed October 2024, NTRB agreed to pay RedChip a $7,500 monthly cash fee, 10,000 shares of common stock, and 50,000 options with a strike price of $4 and a three year term, for 12 months of investor awareness services. Once the options received are exercised, RedChip intends to and will, if possible, sell all of its shares immediately, and you may be buying as RedChip is selling. The CEO of RedChip purchased 4,908 shares of NTRB common stock and may sell those shares at any time, including when you are buying. NTRB also agreed to pay RedChip a one-time $50,000 fee for a 10-day national TV ad campaign that aired weekdays from March 25 through April 5, 2024, a one-time $22,500 dollar fee for a national TV ad campaign aired weekdays from June 17 through June 21, 2024, a one-time $20,000 dollar fee for a national TV ad campaign aired weekdays from June 27 to July 2, 2024, and a one-time $20,000 dollar fee for a national TV ad campaign aired weekdays from September 19 to October 18, 2024.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.